352P - The Prognostic Role of Indicators of Systemic Inflammatory Response in Patients with Glioblastoma

Date 10 September 2017
Event ESMO 2017 Congress
Session Poster display session
Topics Central Nervous System Malignancies
Presenter Vildan Kaya
Citation Annals of Oncology (2017) 28 (suppl_5): v109-v121. 10.1093/annonc/mdx366
Authors V. Kaya1, M. Yildirim2, G. Yazıcı3, A.Y. Yalçın4, N. Orhan5, A. Güzel6
  • 1Department Of Radiation Oncology, Medstar Antalya Hospital, 07000 - Antalya/TR
  • 2İnternal Medicine, Bahçeşehir Üniversitesi, 27090 - Gaziantep/TR
  • 3Department Of Radiation Oncology, Hacettepe University, Ankrar/TR
  • 4Department Of Radiation Oncology, Suleyman Demirel University, Isparta/TR
  • 5Department Of Biochemistry, Medicalpark Gaziantep Hospital, Gaziantep/TR
  • 6Department Of Neurosurgery, Bahçeşehir Üniversitesi, 27090 - Gaziantep/TR



High-grade gliomas, among which glioblastomas are the most frequently observed histologic subtype, are the most common primary brain tumors in adults. The standard treatment for glioblastoma consists of maximal safe resection, followed by concomitant chemoradiotherapy. It was reported that inflammatory response plays a major role in malignancy, including tumor progression. This study aimed to determine the prognostic role of the neutrophil to lymphocyte ratio (NLR) and the thrombocyte to lymphocyte ratio (PLR)—both indicators of systemic inflammatory response (SIR)—in patients with glioblastoma.


This study retrospectively evaluated 90 patients that were treated for glioblastoma.


Median follow-up time was 11.3 months (range: 1-70 months). The 1-year and 2-year overall survival rates were 55.2% and 19.5%, respectively. Univariate analysis showed that there wasn’t a correlation between overall survival and gender (p = 0.184), comorbid diseases (p = 0.30), clinical presentation (p = 0.884), or tumor lateralization (p = 0.159). The prognostic factors that affected survival—other than SIR—were Eastern Cooperative Oncology Group (ECOG) performance status (p = 0.003), and tumor localization (p = 0.006). Multivariate analysis showed that overall survival was significantly correlated with SIR based on NLR (HR: 2.41), and ECOG performance status (HR: 1.53).


These findings confirm that the NLR value obtained from peripheral blood prior to treatment can be used as a prognostic factor in patients with glioblastoma. It is known that a high NLR value (NLR ≥5) is indicative of aggressive disease with decreased survival; therefore, aggressive treatment modalities can be offered to this selected patient population.

Clinical trial identification

Legal entity responsible for the study

Mustafa Yıldırım




All authors have declared no conflicts of interest.